

**Efficacy of late Hematopoietic Stem Cell Mobilization 35-40 hours after administration of Plerixafor**

Vikas Bhushan, MD  
Attending Physician, Stem Cell Transplantation, Medical City Hospital  
Dallas, TX

ASBMT  
CIBMTR  
LMBSSA

---

---

---

---


---

---

---

---

**Plerixafor**



Cyclam Rings connected by a Methylene linker

ASBMT  
CIBMTR  
LMBSSA

---

---

---

---

---

---

---

---

**Learning Objective**

- Compare the efficacy of Plerixafor when administered during and beyond the recommended 10 to 14 hour (vs 35 to 40 hrs) window before stem cell collection

ASBMT  
CIBMTR  
LMBSSA

---

---

---

---

---

---

---

---

### Plerixafor in Hematopoietic Stem Cell Mobilization

- CXCR4/CXCL12 interaction important in retention of HSC in bone marrow
- Plerixafor inhibits CXCR4 receptor, blocking binding with CXCL 12
- Initially investigated as an anti-HIV drug
- Can overcome known risk factors for poor stem cell mobilization
- Reduces mobilization failure rate from 30% to <10%

Fricker SP et al Biochem Pharmacol 2006

ASBMT  
CIBMTR

---

---

---

---

---

---

---

---

### Plerixafor: Pharmacology

- Pivotal study in C3H/HeJ mice: peak CFU (colony forming units) 1hr after s/c injection, dose dependant and returned to baseline in 24 hours

#### Humans

- Peak plasma concentration 30mins after s/c administration
- Elimination half life of 4.6 hours
- Peak CD34+ cells 10-14 hours after dose
- Synergistic effect with G-CSF

Broxmeyer HE et al, J Exp Med 2005

Harvey RD et al Biol Blood Marrow Transplant 2013

ASBMT  
CIBMTR

---

---

---

---

---

---

---

---

### Temporal restrictions in Plerixafor Administration

- Labeling requires administration approximately 11 hours before apheresis-> administration 10pm followed by collection next morning
- Limited data in humans on effect on hematopoietic stem cell collection beyond the 14 hour period
- Successful mobilization with administration 17 hrs prior to apheresis-> administration 4pm followed by collection next morning

Harvey RD et al Biol Blood Marrow Transplant 2013

ASBMT  
CIBMTR

---

---

---

---

---

---

---

---

**Late HSC Mobilization Post Plerixafor**

- Retrospective analysis
- Total Number: 7 (3M/4F)
- Age: 39-72 years; Median 69
- Diagnosis:
 

|                      |   |
|----------------------|---|
| Multiple Myeloma     | 5 |
| Non-Hodgkin Lymphoma | 2 |
- Prior Chemotherapy
 

|  |
|--|
| 6/7 $\geq$ 3 prior chemotherapy regimens |
| 1/7 Hyper-CVAD 8 cycles                  |

ASBMT CIBMTR

---

---

---

---

---

---

---

---

**Mobilization Regimens**

- G-CSF + Plerixafor: 1
- Chemotherapy Mobilization 6
 

|                                   |   |
|-----------------------------------|---|
| - DPACE/DCEP+GCSF+Plerixafor      | 3 |
| - Hyper-CVAD+GCSF+Plerixafor      | 1 |
| - Cylophosphamide+GCSF+Plerixafor | 1 |
| - RICE+GCSF+Plerixafor            | 1 |

ASBMT CIBMTR

---

---

---

---

---

---

---

---

**Indication for Plerixafor Administration**

- Peripheral CD34 + > 10/ $\mu$ l, with failed mobilization (CD34+ 12.1/ $\mu$ l) 1
- Peripheral CD 34+ < 10/ $\mu$ l 6
  - (0.17-5.29/ $\mu$ l, Median 0.99/ $\mu$ l)
- Drug was administered only in patients failing mobilization

ASBMT CIBMTR

---

---

---

---

---

---

---

---

**Dosage and Timing**

- 0.24mg/kg subcutaneously
- Timing: 11-17 hrs prior to apheresis
- First day of Plerixafor administration (Day 1:1<sup>st</sup> day of chemotherapy/G-CSF)
  - Combination Chemotherapy 15-19
  - Cyclophosphamide 14
  - G-CSF alone 6
- Plerixafor administered till minimum target CD34+cells/kg body weight achieved ( $2 \times 10^6$  /  $4 \times 10^6$  CD34+ cells/kg)
- Additional collection following day with G-CSF alone: 35-40 hours after last dose of Plerixafor
- Total Number of Doses 1-4 (Median 3)

---

---

---

---

---

---

---

---

**CD34+ cells(/µl) collection 11-16 hours & 35-40 hours post Plerixafor**

| DIAGNOSIS | MOBILIZATION REGIMEN | 11-16 HOURS | 35-40 HOURS |
|-----------|----------------------|-------------|-------------|
| Myeloma   | DPACE                | 3.12        | 3.13        |
| Myeloma   | DPACE                | 2.19        | 2.37        |
| Myeloma   | DCEP                 | 0.72        | 0.78        |
| NHL       | CYCLOPHOS            | 0.37        | 0.41        |
| NHL       | RICE                 | 2.74        | 3.11        |
| Myeloma   | HYPERCVAD            | 4.21        | 5.25        |
| Myeloma   | No Chemo             | 0.73        | 1.4         |

---

---

---

---

---

---

---

---

**CD34+ collection: 11-16 hrs vs. 35-40 hrs post G-CSF + Plerixafor**

- Average collection 11-16 hours : 0.49-4.21 (Total 1-4 days, Median 3) Mean 1.21
- Collection 11-16 hours post last dose: 0.37-4.21 Mean 2.01
- Collection 35-40 hours post last dose: 0.41-5.25 Mean 2.21
- Collection in patient with G+P alone:
  - 11 hours 0.73
  - 35 hours 1.40

---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

### Possible Explanations for Late HSC Mobilization post Plerixafor

- Unusual patient population
- Late count recovery with continued effect of G-CSF
- Kinetics of Plerixafor effect on CD34+ cells in humans remains to be properly understood

---

---

---

---

---

---

---

---

### Conclusions

- Collection 35-40 hours post last dose of Plerixafor was superior/comparable to the traditional 11-14 hour window
- Need for additional studies to determine the effects of Plerixafor on CD34+ cells beyond the 11-14 hour period
- Alternate Plerixafor mobilization protocols possible with significant cost implications

---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



**Plerixafor in stem cell mobilization**

*Which of the following statements is correct with regards to this study?*

- A. Patients were at average risk for mobilization failure and had superior PBSC collection 35 hours post Plerixafor
- B. Patients were at high risk for mobilization failure and had superior collection in the traditional 11-16 hours post Plerixafor
- C. Patients were at high risk for mobilization failure and had superior/comparable collection 35-40 hours post Plerixafor
- D. Attempting to collect PBSC beyond the day after last dose of Plerixafor is futile and is waste of resources

---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---